DYAI

Dyadic International, Inc. [DYAI] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

DYAI Stock Summary

Top 10 Correlated ETFs

DYAI


Top 10 Correlated Stocks

DYAI


In the News

11:23 30 Nov 2023 DYAI

Dyadic International, Inc. (DYAI) Q3 2023 Earnings Call Transcript

Dyadic International, Inc. (NASDAQ:DYAI ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Mark Emalfarb - President, Chief Executive Officer Ping Rawson - Chief Financial Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Paul Rosenbaum - SWR Operator Good evening, and welcome to the Dyadic International's Third Quarter 2023 Financial Results Conference Call. Currently all participants are in a listen-only mode.

08:30 30 Nov 2023 DYAI

Dyadic to Present at Industry Events in November

JUPITER, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be participating and presenting at the following industry events during the month of November: Cultured Meat Symposium 2023, November 2-3, 2023StarBase, Las VegasJoseph Hazelton, Chief Business Officer 8th International Vaccines Research & Development, November 6-8, 2023Hilton Baltimore BWI Airport Hotel, Linthicum Heights, MDMark Emalfarb, President, and Chief Executive Officer “Next-Gen Vaccines without the Right Platform Limit Pandemic Effectiveness C1, Protective, Rapid, High Yield, Low-Cost Global Solution”  Presentation Time: Monday, November 6, 2023, 2:10 PM – 2:30 PM ET BARDA Industry Day 2023, November 13-14, 2023Grand Hyatt Washington, Washington, DCJoseph Hazelton, Chief Business Officer Vaccines Summit, November 13-15, 2023Sheraton Boston Needham Hotel, Boston, MAMark Emalfarb, President, and Chief Executive Officer “Rapid development and flexible scale of complex recombinant proteins and antigens including ferritin nanoparticles for infectious diseases including COVID-19 and seasonal and pandemic influenza” Presentation Time: Wednesday, November 15, 2023, 1:40 PM – 2:00 PM ET If you would like to connect with Dyadic's management at any of these events, you may request a one-on-one meeting at jlavalley@dyadic.com About Dyadic International, Inc. Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health.

04:30 30 Nov 2023 DYAI

Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

JUPITER, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that it will report its financial results for the third quarter 2023 and host a corporate update conference call on Wednesday, November 8, 2023.

08:30 30 Nov 2023 DYAI

Dyadic to Present at Industry and Investor Events in October

JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be presenting at the following industry and investor events during the month of October: Enzyme Engineering XXVII, October 1-6, 2023Park Royal Hotel, SingaporeDr. Ronen Tchelet, Chief Scientific Officer “The use of in silico analysis to engineer the best immunogenic epitope and produce the corresponding prophylactic antigen-based vaccines with C1 production platform in order to rapidly respond to viral pandemics” Wednesday, October 4, 2023, 11:00 AM – 11:30 AM LD Mirco Main Event XVI, October 3-5, 2023Luxe Sunset Blvd Hotel, Los Angeles, CAMark Emalfarb, President, and Chief Executive Officer “Next Generation Proteins for World Health, Nutrition and Wellness” Wednesday, October 4, 2023, 8:00 AM – 8:25 AM World Vaccine Congress Europe, October 16-19, 2023Fira de Barcelona Montjuic, Barcelona, SpainMark Emalfarb, President, and Chief Executive Officer “Rapid development and flexible scale manufacturing of complex recombinant proteins and antigens including ferritin nanoparticles for seasonal and pandemic influenza vaccines” Wednesday, October 18, 2023, 11:45 AM – 12:00 PM If you would like to connect with Dyadic's management at any of the events, you may request a one-on-one meeting at jlavalley@dyadic.com.

04:30 30 Nov 2023 DYAI

Dyadic to Present at BioProcess International

JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.

11:41 30 Nov 2023 DYAI

Dyadic International, Inc. (DYAI) Q2 2023 Earnings Call Transcript

Dyadic International, Inc. (NASDAQ:DYAI ) Q2 2023 Earnings Conference Call August 9, 2023 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Dick Williams - Williams Research Group Robert Smith - Center for Performance Investing Tony Bowers - Intro Act Operator Good evening, and welcome to Dyadic International's Second Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

04:30 30 Nov 2023 DYAI

Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

JUPITER, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that it will report its financial results for the second quarter 2023 and host a corporate update conference call on Wednesday, August 9, 2023.

10:19 30 Nov 2023 DYAI

Dyadic International, Inc. (DYAI) Q1 2023 Earnings Call Transcript

Dyadic International, Inc. (NASDAQ:DYAI ) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Operator Good evening, and welcome to Dyadic International's First Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

04:30 30 Nov 2023 DYAI

Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

JUPITER, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it will report its financial results for first quarter 2023 and host a corporate update conference call on Wednesday, May 10, 2023.

09:51 30 Nov 2023 DYAI

Dyadic reports 21.9% revenue rise, $12.7M in cash for full year 2022 as it rapidly advances technology

Dyadic International Inc (NASDAQ:DYAI) posted its financial results for the year ended 2022 with revenue surging 21.9% year-over-year on the back of license agreements as it rapidly advanced its technology. For the year ended December 31, 2022, the Jupiter, Florida-based biotechnology platform company reported research and development (R&D) revenue of $2.93 million, compared to $2.40 million for the year ended December 31, 2021.

DYAI Financial details

Company Rating
Neutral
Market Cap
54.16M
Income
-5.7M
Revenue
2.96M
Book val./share
0.27
Cash/share
0.28
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
08 Nov 2023
P/E
-8.92
Forward P/E
7.08
PEG
1.57
P/S
17.2
P/B
6.65
P/C
6.32
P/FCF
-6.79
Quick Ratio
5.9
Current Ratio
6.24
Debt / Equity
0.02
LT Debt / Equity
0.01
-
-
EPS (TTM)
-0.2
EPS next Y
0.25
EPS next Q
-0.06
EPS this Y
-28.26%
EPS next Y
-225.63%
EPS next 5Y
85.93%
EPS last 5Y
9.46%
Revenue last 5Y
17.73%
Revenue Q/Q
-52.57%
EPS Q/Q
-25.03%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
12.19%
Inst Trans
0.78%
ROA
-62%
ROE
-59%
ROC
-1.06%
Gross Margin
21%
Oper. Margin
-280%
Profit Margin
-193%
Payout
-
Shs Outstand
28.81M
Shs Float
18.7M
-
-
-
-
Target Price
-
52W Range
1.12-2.4
52W High
-11.5%
52W Low
+77%
RSI
53
Rel Volume
0.96
Avg Volume
24.29K
Volume
23.39K
Perf Week
-2.21%
Perf Month
-1.12%
Perf Quarter
-20.27%
Perf Half Y
-20.63%
-
-
-
-
Beta
0.616
-
-
Volatility
0.04%, 0.08%
Prev Close
0.28%
Price
1.77
Change
-3.01%

DYAI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.050.060.060.090.1
Net income per share
-0.21-0.31-0.34-0.46-0.33
Operating cash flow per share
-0.16-0.21-0.24-0.41-0.28
Free cash flow per share
-0.16-0.21-0.24-0.41-0.28
Cash per share
1.491.271.060.730.45
Book value per share
1.531.331.040.660.39
Tangible book value per share
1.531.331.040.660.39
Share holders equity per share
1.531.331.040.660.39
Interest debt per share
0.03000-0.01
Market cap
52.3M139.88M147.8M125.83M34.89M
Enterprise value
49.92M135.06M127.16M110.08M29.09M
P/E ratio
-9.19-16.84-15.85-9.74-3.72
Price to sales ratio
40.3783.2192.2652.3411.91
POCF ratio
-11.87-24.19-22.48-11.16-4.32
PFCF ratio
-11.87-24.19-22.48-11.16-4.32
P/B Ratio
1.233.95.26.843.15
PTB ratio
1.233.95.26.843.15
EV to sales
38.5380.3479.3845.799.93
Enterprise value over EBITDA
-6.61-14.64-12.48-6.82-2.89
EV to operating cash flow
-11.33-23.35-19.34-9.76-3.6
EV to free cash flow
-11.33-23.35-19.34-9.76-3.6
Earnings yield
-0.11-0.06-0.06-0.1-0.27
Free cash flow yield
-0.08-0.04-0.04-0.09-0.23
Debt to equity
00000
Debt to assets
00000
Net debt to EBITDA
0.320.522.030.980.58
Current ratio
50.3122.4418.328.225.48
Interest coverage
-8.4900026.59
Income quality
0.770.70.710.860.83
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
3.493.283.82.792.19
Research and developement to revenue
2.562.352.413.491.54
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
0.360.71.030.740.64
Graham number
2.663.032.812.631.7
ROIC
-0.15-0.26-0.35-0.79-0.88
Return on tangible assets
-0.13-0.22-0.31-0.61-0.68
Graham Net
1.491.241.010.630.36
Working capital
41.9M34.05M28.16M18.45M10.97M
Tangible asset value
42.45M35.86M28.45M18.39M11.09M
Net current asset value
41.9M34.05M28.16M18.1M10.8M
Invested capital
00000
Average receivables
940.36K1.13M772.5K389.33K380.25K
Average payables
414.66K626.22K978.24K1.28M1.41M
Average inventory
634.32K126.72K000
Days sales outstanding
315.52247.292.6156.5248.37
Days payables outstanding
109.81235.89259.51290.57219.41
Days of inventory on hand
90.050000
Receivables turnover
1.161.483.946.467.55
Payables turnover
3.321.551.411.261.66
Inventory turnover
4.050000
ROE
-0.13-0.23-0.33-0.7-0.85
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.030.030.030.030.01
Net income per share
-0.06-0.070-0.07-0.06
Operating cash flow per share
-0.06-0.06-0.08-0.06-0.07
Free cash flow per share
-0.06-0.06-0.08-0.06-0.07
Cash per share
0.50.450.410.350.28
Book value per share
0.440.390.380.310.27
Tangible book value per share
0.440.390.380.310.27
Share holders equity per share
0.440.390.380.310.27
Interest debt per share
00-0.0400.01
Market cap
54.23M34.89M51.2M55.61M55.32M
Enterprise value
47.49M29.09M44.82M49.76M48.06M
P/E ratio
-7.97-4.2193.01-6.46-8.57
Price to sales ratio
61.6546.9152.3466.42139.32
POCF ratio
-30.53-20.75-23.41-33.6-28.2
PFCF ratio
-30.53-20.75-23.41-33.6-28.2
P/B Ratio
4.33.154.746.197.23
PTB ratio
4.33.154.746.197.23
EV to sales
53.9939.1245.8359.44121.05
Enterprise value over EBITDA
-25.85-13.3-22.1-22.01-28.36
EV to operating cash flow
-26.74-17.3-20.5-30.07-24.5
EV to free cash flow
-26.74-17.3-20.5-30.07-24.5
Earnings yield
-0.03-0.060-0.04-0.03
Free cash flow yield
-0.03-0.05-0.04-0.03-0.04
Debt to equity
00000.02
Debt to assets
00000.02
Net debt to EBITDA
3.672.653.142.584.28
Current ratio
6.255.486.835.536.24
Interest coverage
-34.3233.131.8700
Income quality
0.980.782.290.771.22
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.572.241.511.683.23
Research and developement to revenue
0.850.790.831.11.8
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
0.570.650.340.40.71
Graham number
0.770.80.20.720.58
ROIC
-0.14-0.190.03-0.24-0.2
Return on tangible assets
-0.11-0.150.01-0.19-0.17
Graham Net
0.420.360.360.30.24
Working capital
12.54M10.97M10.93M9.07M7.63M
Tangible asset value
12.61M11.09M10.8M8.99M7.65M
Net current asset value
12.32M10.8M10.8M8.98M7.48M
Invested capital
00000.02
Average receivables
733.46K333.76K586.23K793.91K615.68K
Average payables
936.22K1.03M1.02M838.12K753.01K
Average inventory
00000
Days sales outstanding
28.5746.9972.1686.496.95
Days payables outstanding
116.04163.0595.38102.82510.19
Days of inventory on hand
00000
Receivables turnover
3.151.921.251.040.93
Payables turnover
0.780.550.940.880.18
Inventory turnover
00000
ROE
-0.13-0.190.01-0.24-0.21
Capex per share
00000

DYAI Frequently Asked Questions

What is Dyadic International, Inc. stock symbol ?

Dyadic International, Inc. is a US stock , located in Jupiter of Fl and trading under the symbol DYAI

What is Dyadic International, Inc. stock quote today ?

Dyadic International, Inc. stock price is $1.77 today.

Is Dyadic International, Inc. stock public?

Yes, Dyadic International, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap